Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib in metastatic colorectal cancer (3rd line+)
NCT02196688Phase 2Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Apr 2014
- Primary completion
- Apr 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in metastatic colorectal cancer (mCRC), sponsored by Hutchison MediPharma (HMP). Started Apr 2014; status: completed.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02196688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02196688.